Article Figures & Data
Figures
- Fig 1.
20-year-old woman with biopsy-proved high-grade glioma.
A, Contrast-enhanced axial T1-weighted image (600/14/1 [TR/TE/NEX]) demonstrates an ill-defined nonenhancing mass (arrow) in the right frontal region. The lack of enhancement on the conventional MR image suggests a low-grade glioma.
B, Axial T2-weighted image (3400/119/1) shows increased signal intensity in the mass, with minimal peritumoral edema. This mass was graded as a low-grade glioma with conventional MR imaging because of lack of enhancement, minimal edema, no necrosis, and no mass effect.
C, Gradient-echo (1000/54) axial perfusion MR image with rCBV color overlay map shows increased perfusion with a high rCBV of 7.72, in keeping with a high-grade glioma.
D, Spectrum from proton MR spectroscopy with the PRESS sequence (1500/144) demonstrates markedly elevated Cho and decreased NAA with a Cho/NAA ratio of 2.60, as well as increased lactate (Lac), in keeping with a high-grade glioma.
- Fig 2.
43-year-old man with biopsy-proved low-grade glioma.
A, Contrast-enhanced axial T1-weighted image (600/14/1) demonstrates a peripherally enhancing mass (arrow) in the right frontal region. The presence of contrast material enhancement on the conventional MR image would suggest a high-grade glioma.
B, Axial T2-weighted image (3400/119/1) shows marked peritumoral edema with possible necrosis and blood products. This mass was graded as a high-grade glioma with conventional MR imaging because of the contrast material enhancement, heterogeneity, blood products, possible necrosis, and degree of edema.
C, Gradient-echo (1000/54) axial perfusion MR image with rCBV color overlay map shows a low rCBV of 1.70, in keeping with a low-grade glioma.
D, Spectrum from proton MR spectroscopy with the PRESS sequence (1500/144) demonstrates elevated Cho and slightly decreased NAA with a Cho/NAA ratio of 0.90, which is more in keeping with a low-grade glioma.
- Fig 3.
ROC curves for rCBV plus metabolites, rCBV alone, Cho/Cr, and Cho/NAA demonstrate superior sensitivity and specificity of rCBV plus metabolites and rCBV alone compared with conventional MR imaging (cMRI, green asterisk) for glioma grading.
Tables
- TABLE 1:
Threshold values for rCBV for differentiation between low- and high-grade gliomas
Description rCBV Sensitivity Specificity PPV NPV C2 Error C1 Error Minimum C2 Error* 1.75 95.0 57.5 87.0 79.3 14.4 23.8 Minimum C1 Error† 2.97 72.5 87.5 94.6 51.5 23.8 20.0 Same sensitivity as cMRI 2.97 72.5 87.5 94.6 51.5 23.8 20.0 Same specificity as cMRI 2.18 87.5 65.0 88.2 63.4 18.1 23.0 Note.—Conventional MR imaging (cMRI) sensitivity 72.5%, specificity 65.0%, PPV 86.1%, NPV 44.1%, C2 error 29.4%, and C1 error 31.8%.
* C2 = the percentage of observed data points misclassified.
† C1 = 1 − (sensitivity + specificity)/2. This maximizes the average of sensitivity and specificity.
- TABLE 2:
Threshold values for Cho/Cr ratio for differentiation between low- and high-grade gliomas
Description Cho/Cr Sensitivity Specificity PPV NPV C2 Error C1 Error Minimum C2 Error* 1.08 97.5 12.5 77.0 62.5 23.8 45.0 Minimum C1 Error† 1.56 75.8 47.5 81.2 39.6 31.3 38.3 Same sensitivity as cMRI 1.61 72.5 50.0 81.3 37.7 33.1 38.8 Same specificity as cMRI 1.88 55.0 65.0 83.5 33.3 41.9 38.8 Note.—Conventional MR imaging (cMRI) sensitivity 72.5%, specificity 65.0%, PPV 86.1%, NPV 44.1%, C2 error 29.4%, and C1 error 31.8%.
* C2 = the percentage of observed data points misclassified.
† C1 = 1 − (sensitivity + specificity)/2. This maximizes the average of sensitivity and specificity.
- TABLE 3:
Threshold values for Cho/NAA ratio for differentiation between low- and high-grade gliomas
Description Cho/NAA Sensitivity Specificity PPV NPV C2 Error C1 Error Minimum C2 Error* 0.75 96.7 10.0 76.3 50.0 25.0 46.7 Minimum C1 Error† 1.60 74.2 62.5 85.6 44.6 28.8 31.7 Same sensitivity as cMRI 1.66 72.5 62.5 85.3 43.1 30.0 32.5 Same specificity as cMRI 1.78 67.5 65.0 85.3 40.0 33.1 33.8 Note.—Conventional MR imaging (cMRI) sensitivity 72.5%, specificity 65.0%, PPV 86.1%, NPV 44.1%, C2 error 29.4%, and C1 error 31.8%.
* C2 = the percentage of observed data points misclassified.
† C1 = 1 − (sensitivity + specificity)/2. This maximizes the average of sensitivity and specificity.
- TABLE 4:
rCBV, Cho/Cr ratio, and Cho/NAA ratio together for differentiation between low- and high-grade glioma
Description Sensitivity Specificity PPV NPV C2 Error C1 Error Minimum C2 Error* 93.3 60.0 87.5 75.0 15.0 23.3 Minimum C1 Error† 70.8 92.5 96.6 51.4 23.7 18.3 Same sensitivity as cMRI 72.5 87.5 94.6 51.5 23.8 20.0 Same specificity as cMRI 89.2 65.0 88.4 66.7 16.9 22.9 Note.—Conventional MR imaging (cMRI) sensitivity 72.5%, specificity 65.0%, PPV 86.1%, NPV 44.1%, C2 error 29.4%, and C1 error 31.8%.
* C2 = the percentage of observed data points misclassified.
† C1 = 1 − (sensitivity + specificity)/2. This maximizes the average of sensitivity and specificity.
- TABLE 5:
Perfusion MR measure and metabolite ratios for low- and high-grade gliomas and normal values
Technique and Measure Low-Grade Glioma (n = 40) High-Grade Glioma (n = 120) P Value* Range Mean SD Range Mean SD Perfusion MR imaging rCBV 0.77–9.84 2.14 1.67 0.96–19.80 5.18 3.29 < 0.0001 MR Spectroscopy Cho/Cr 0.85–4.00 1.75 0.60 0.83–13.80 2.43 1.92 0.0121 Cho/NAA 0.60–6.80 1.96 1.43 0.53–28.90 3.22 3.65 0.001 NAA/Cr 0.33–3.60 1.20 0.71 0.10–3.93 0.90 0.62 0.0038 Normal values† Cho/Cr 0.43–1.37 0.88 0.19 0.44–2.00 0.87 0.24 0.425 NAA/Cr 1.11–2.89 1.72 0.41 0.45–4.74 1.73 0.51 0.958 * Mann-Whitney test.
† Ratios in normal-appearing contralateral brain.
In this issue
Jump to section
Related Articles
Cited By...
- Imaging-Based Algorithm for the Local Grading of Glioma
- Effects of Susceptibility Artifacts on Perfusion MRI in Patients with Primary Brain Tumor: A Comparison of Arterial Spin-Labeling versus DSC
- Prognostic Predictions for Patients with Glioblastoma after Standard Treatment: Application of Contrast Leakage Information from DSC-MRI within Nonenhancing FLAIR High-Signal-Intensity Lesions
- Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma
- Texture Analysis in Cerebral Gliomas: A Review of the Literature
- Ultrasensitive Immunoprofiling of Plasma Extracellular Vesicles Identifies Syndecan-1 as a Potential Tool for Minimally Invasive Diagnosis of Glioma
- Glioma Through the Looking GLASS: the Glioma Longitudinal Analysis consortium, molecular evolution of diffuse gliomas
- Glioma grade map: a machine-learning based imaging biomarker for tumor characterization
- Optimization of Acquisition and Analysis Methods for Clinical Dynamic Susceptibility Contrast MRI Using a Population-Based Digital Reference Object
- Added Value of Spectroscopy to Perfusion MRI in the Differential Diagnostic Performance of Common Malignant Brain Tumors
- MR Imaging Features of Anaplastic Pleomorphic Xanthoastrocytoma Mimicking High-Grade Astrocytoma
- Metabolic Imaging of the Human Brain with Hyperpolarized 13C Pyruvate Demonstrates 13C Lactate Production in Brain Tumor Patients
- Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project
- MRI Features Can Predict 1p/19q Status in Intracranial Gliomas
- Improved Spatiotemporal Resolution of Dynamic Susceptibility Contrast Perfusion MRI in Brain Tumors Using Simultaneous Multi-Slice Echo-Planar Imaging
- Discrimination between Glioma Grades II and III Using Dynamic Susceptibility Perfusion MRI: A Meta-Analysis
- Combining Diffusion Tensor Metrics and DSC Perfusion Imaging: Can It Improve the Diagnostic Accuracy in Differentiating Tumefactive Demyelination from High-Grade Glioma?
- Automated Processing of Dynamic Contrast-Enhanced MRI: Correlation of Advanced Pharmacokinetic Metrics with Tumor Grade in Pediatric Brain Tumors
- MRI Evaluation of Non-Necrotic T2-Hyperintense Foci in Pediatric Diffuse Intrinsic Pontine Glioma
- Differentiation of Low- and High-Grade Gliomas Using High b-Value Diffusion Imaging with a Non-Gaussian Diffusion Model
- Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange
- Mitotic Activity in Glioblastoma Correlates with Estimated Extravascular Extracellular Space Derived from Dynamic Contrast-Enhanced MR Imaging
- Contrast Leakage Patterns from Dynamic Susceptibility Contrast Perfusion MRI in the Grading of Primary Pediatric Brain Tumors
- Improved Brain Tumor Classification by Sodium MR Imaging: Prediction of IDH Mutation Status and Tumor Progression
- Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma
- Comparison of the Diagnostic Accuracy of DSC- and Dynamic Contrast-Enhanced MRI in the Preoperative Grading of Astrocytomas
- ASFNR Recommendations for Clinical Performance of MR Dynamic Susceptibility Contrast Perfusion Imaging of the Brain
- Arterial Spin-Labeling Perfusion MRI Stratifies Progression-Free Survival and Correlates with Epidermal Growth Factor Receptor Status in Glioblastoma
- MRI Grading versus Histology: Predicting Survival of World Health Organization Grade II-IV Astrocytomas
- Comparison of Multiple Parameters Obtained on 3T Pulsed Arterial Spin-Labeling, Diffusion Tensor Imaging, and MRS and the Ki-67 Labeling Index in Evaluating Glioma Grading
- Advanced Magnetic Resonance Imaging of the Physical Processes in Human Glioblastoma
- Comparison of Perfusion, Diffusion, and MR Spectroscopy between Low-Grade Enhancing Pilocytic Astrocytomas and High-Grade Astrocytomas
- Diffusion Imaging for Tumor Grading of Supratentorial Brain Tumors in the First Year of Life
- Arterial Spin-Labeling Assessment of Normalized Vascular Intratumoral Signal Intensity as a Predictor of Histologic Grade of Astrocytic Neoplasms
- Perfusion Measurement in Brain Gliomas with Intravoxel Incoherent Motion MRI
- Arterial Spin-Labeled Perfusion of Pediatric Brain Tumors
- Clinical and research applications of simultaneous positron emission tomography and MRI
- Differentiation between Oligodendroglioma Genotypes Using Dynamic Susceptibility Contrast Perfusion-Weighted Imaging and Proton MR Spectroscopy
- Super-Resolution Track Density Imaging of Glioblastoma: Histopathologic Correlation
- Multimodal MR Imaging (Diffusion, Perfusion, and Spectroscopy): Is It Possible to Distinguish Oligodendroglial Tumor Grade and 1p/19q Codeletion in the Pretherapeutic Diagnosis?
- Multimodal Elucidation of Choline Metabolism in a Murine Glioma Model Using Magnetic Resonance Spectroscopy and 11C-Choline Positron Emission Tomography
- Semi-automated and automated glioma grading using dynamic susceptibility-weighted contrast-enhanced perfusion MRI relative cerebral blood volume measurements
- 3'-Deoxy-3'-18F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients
- Diagnostic Accuracy of Dynamic Contrast-Enhanced MR Imaging Using a Phase-Derived Vascular Input Function in the Preoperative Grading of Gliomas
- Imaging Characteristics of Oligodendrogliomas That Predict Grade
- MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice
- The Added Value of Apparent Diffusion Coefficient to Cerebral Blood Volume in the Preoperative Grading of Diffuse Gliomas
- Does MR Perfusion Imaging Impact Management Decisions for Patients with Brain Tumors? A Prospective Study
- Correlations between Perfusion MR Imaging Cerebral Blood Volume, Microvessel Quantification, and Clinical Outcome Using Stereotactic Analysis in Recurrent High-Grade Glioma
- Diagnosis and treatment in neuro-oncology: an oncological perspective
- Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours
- Biology, genetics and imaging of glial cell tumours
- Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications
- Perfusion CT Imaging of Brain Tumors: An Overview
- Multimodality Assessment of Brain Tumors and Tumor Recurrence
- Prospective Analysis of Parametric Response Map-Derived MRI Biomarkers: Identification of Early and Distinct Glioma Response Patterns Not Predicted by Standard Radiographic Assessment
- Value of 1H-magnetic resonance spectroscopy chemical shift imaging for detection of anaplastic foci in diffusely infiltrating gliomas with non-significant contrast-enhancement
- Quantitative Diffusion-Weighted and Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Analysis of T2 Hypointense Lesion Components in Pediatric Diffuse Intrinsic Pontine Glioma
- Recent advances in imaging epilepsy
- Combination of high-resolution susceptibility-weighted imaging and the apparent diffusion coefficient: added value to brain tumour imaging and clinical feasibility of non-contrast MRI at 3 T
- Enhancing Fraction in Glioma and Its Relationship to the Tumoral Vascular Microenvironment: A Dynamic Contrast-Enhanced MR Imaging Study
- Semiquantitative Assessment of Intratumoral Susceptibility Signals Using Non-Contrast-Enhanced High-Field High-Resolution Susceptibility-Weighted Imaging in Patients with Gliomas: Comparison with MR Perfusion Imaging
- Cerebral Blood Volume Measurements by Perfusion-Weighted MR Imaging in Gliomas: Ready for Prime Time in Predicting Short-Term Outcome and Recurrent Disease?
- Tumor Cell Metabolism Imaging
- Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading?
- Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors
- Diagnosis and Treatment of Recurrent High-Grade Astrocytoma
- Magnetic Resonance Angiography Visualization of Abnormal Tumor Vasculature in Genetically Engineered Mice
- Comparative Overview of Brain Perfusion Imaging Techniques